

CSPC Named Among “Most Honored Companies” in Asia by Institutional Investor Again

Hong Kong, 29 June 2018 - **CSPC Pharmaceutical Group Limited** (“CSPC” or “the company”, HKEx.: 01093) is pleased to announce that the company was recognized as a “Most Honored Company” again in *Institutional Investor’s* annual All-Asia Executive Team survey, and was ranked Top 3 for all the 7 categories in the Health Care & Pharmaceuticals sector, including “Best CEO”.

“2018 All-Asia Executive Team” was held once a year for the recognition of outstanding companies and executive teams. This year, a record total of 3,538 buy-side individuals and 982 sell-side analysts participated in the survey.

CSPC and its executive team stood out among 2,368 companies being nominated across 18 industries and got all the top 3 rankings in all of the 7 categories in the Health Care & Pharmaceuticals sector. Amongst all, the chairman / CEO of the company, Mr. CAI Dong-chen captured first place in “Best CEO” in all sell-side, buy-side and overall rankings.

The followings are the nominations and recognitions that CSPC achieved in “Health Care & Pharmaceuticals” sector:

1. Best CEO – **Mr. CAI Dong-chen** (First Place)
2. Best CFO – **Mr. Eddie Chak** (Second Place)
3. Best IR Professional – **Ms. Winnie Yam** (Second Place)
4. Best IR Program – **CSPC Pharmaceutical Group Limited** (First Place)
5. Best Corporate Governance – **CSPC Pharmaceutical Group Limited** (First Place)
6. Best ESG SRI Metrics – **CSPC Pharmaceutical Group Limited** (First Place)
7. Best Analyst Day – **CSPC Pharmaceutical Group Limited** (First Place)